Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 3,676 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type II Clear all
Completed Phase 3 Interventional Results available

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
40
States / cities
Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Not applicable Interventional

Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes

NCT01886989
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cocoa polyphenols
Dietary Supplement
Lead sponsor
Arpita Basu
Other
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

NCT04466618
View directory record Official record
Conditions
Healthy, Type 2 Diabetes
Interventions
Saline, Exendin-9,39, Saline + Intralipid/Heparin, Exendin-9,39 + Intralipid/Heparin
Biological
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 14, 2026, 11:47 PM EDT
Terminated Phase 4 Interventional Results available

The Relationship of Hemoglobin A1c and Diabetic Wound Healing

NCT01350102
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2, Foot Ulcer, Diabetic
Interventions
Bacitracin, AmeriGel®, Vitamin C
Drug · Dietary Supplement
Lead sponsor
Susan Hassenbein
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 14, 2026, 11:47 PM EDT
Completed No phase listed Observational

Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System

NCT02073058
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
No treatment
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

A Study in Patients With Type 2 Diabetes Mellitus

NCT01435616
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glargine, LY2605541
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
66
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02065752
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 14, 2026, 11:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Adherence to Digital Health Technologies Among Hispanic/Latino Adults With or At Risk of Type 2 Diabetes:

NCT04820348
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Depression, Anxiety, Diet Habit
Interventions
Not listed
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

NCT01262898
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Concord, California • Indianapolis, Indiana • Chevy Chase, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 4 Interventional

Effect of Thiazolidinedione Treatment Vascular Risk Markers

NCT00571506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Vascular Diseases
Interventions
Rosiglitazone, Pioglitazone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

NCT01342484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo, BI1356 low dose, BI1356 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Antonio, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Not applicable Interventional Results available

Dietary Approaches to Stop Hypertension for Diabetes

NCT04286555
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Diabetes type2, Type2 Diabetes, Type 2 Diabetes, Type II Diabetes, Hypertension, High Blood Pressure
Interventions
DASH4D diet, comparison diet, higher sodium, lower sodium
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Not applicable Interventional

The Effect of a Low-fat Vegan Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes

NCT06106035
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese
Interventions
low-fat vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 14, 2026, 11:47 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Huntsville, Alabama • Mobile, Alabama • Sheffield, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 14, 2026, 11:47 PM EDT
Completed No phase listed Observational Results available

Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes

NCT01494298
View directory record Official record
Conditions
Type 2 Diabetes, African American, Cholesterol, Lipoprotein, Apolipoprotein
Interventions
Not listed
Lead sponsor
Mercer University
Other
Eligibility
18 Years to 79 Years · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 4 Interventional Results available

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

NCT01859793
View directory record Official record
Conditions
Diabetes, Atherosclerosis
Interventions
sitagliptin, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 14, 2026, 11:47 PM EDT
Completed No phase listed Observational Results available

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

NCT02197078
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
189,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Not applicable Interventional

Glutathione-rich Foods for Type 2 Diabetes

NCT04386187
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
GSH Foods, Nutrition education about glutathione sources in the diet, Standard of care nutrition education for type 2 diabetes
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 14, 2026, 11:47 PM EDT
Not listed Not applicable Interventional

The Surgical Treatment of Type 2 Diabetes Mellitus in Non-Morbidly Obese Patients: A Community Hospital Study

NCT01323114
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Laparoscopic duodenal exclusion, Conventional Medical Treatment
Procedure · Other
Lead sponsor
McKenzie Health System
Other
Eligibility
20 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Sandusky, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Not applicable Interventional Results available

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

NCT02542631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

NCT01515657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Not applicable Interventional

A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas

NCT00846300
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperlipidemia, Hypertension
Interventions
Physician counseling for health behavior change
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
6
States / cities
Corpus Christi, Texas • Harlingen, Texas • Laredo, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 14, 2026, 11:47 PM EDT
Active, not recruiting Not applicable Interventional

Group Versus Traditional Prenatal Care for Diabetes

NCT03301792
View directory record Official record
Conditions
Pregnancy, Gestational Diabetes, Type 2 Diabetes
Interventions
Group prenatal care
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 14, 2026, 11:47 PM EDT